Bir Devlet Hastanesinde 2013-2018 Döneminde Acınetobacter Enfeksiyonlarında Antibiyotik Duyarlılığı Ve Çoğul Antibiyotik Direnci

Amaç: Bu çalışmada Acinetobacter baumannii suşlarının yıllara göre antibiyotik duyarlılık değişiminin araştırılması ve çoğul antibiyotik direnç oranının belirlenerek geliştirilmesine yardımcı olunması amaçlanmıştır.antibiyotik kullanım politikasının decrease in sensitivity to amikacin, ampicillin-sulbactam, cefepime, ceftriaxone, colistin and tigecycline, while sensitivity to other antibiotics was observed. Multiple antibiotic resistance was examined in a total of 237 A. baumannii isolated. Multidrug resistant MDR resistance was 92 %, Extensively Drug Resistant XDR resistance was 84 % and Pan Drug Resistant PDR resistance was 3 %.Conclusion: It is observed that resistance against some antibiotics has increased in A. baumannii over the years, and resistance to some antibiotics has decreased. It seems that our XDR resistance rate is very high. Our PDR resistance rate is higher than that of America, but lower than many European countries. In the other hand our result is lower than the average of Turkey

Anahtar Kelimeler:

Acinetobacter enfeksiyonları, bakteri duyarlılık testi, çoklu antibakteriyel ilaç direnci

Antıbıotıc Sensıtıvıty And Multıple Antıbıotıc Resıstance Of Acınetobacter Infectıons In A State Hospıtal In The Perıod 2013-2018

Objective: In this study, it was aimed to investigate the change of antibiotic susceptibility of Acinetobacter baumannii strains over the years and to help develop antibiotic use policy by determining the multiple antibiotic resistance rate.Methods: Acinetobacter species isolated from various clinical samples sent to Necip FazılCity Hospital Microbiology Laboratory between January 2013 and December 2018 were included. Vitek 2 Compact bioMérieux-SE, France automated systems were used for the identification and antibiotic susceptibility of the isolates.Results: Acinetobacter isolates were isolated at the most from tracheal aspirate samples n=73; 35% and samples sent from Anesthesia and Reanimation intensive care unit n=160; 68 % . The distribution of antibiotic sensitivity percentages % was given as yearly, three-year averages for 2013-2015, 2016-2018, and the total average for 2013-2018. In the study period, the highest sensitivity was determined to colistin at 97 % and the lowest to ceftriaxone at 5 %. When the antibiotic sensitivity rates of A. baumannii are evaluated roughly; In the period of 2016-2018, compared to 2013-2015, there was a Acinetobacter baumannii kompleksi, idrar yolu enfeksiyonu, cilt ve yumuşak doku enfeksiyonları gibi çeşitli enfeksiyonlara neden olabilir. Pnömoni ve kan dolaşımı enfeksiyonlarında ölüm oranı yüksek olan önemli bir patojendir 1 .Hastanede yatan hastaların kolonizasyon ve enfeksiyonunda A. baumannii türlerinin önemli bir rol oynadığı bilinmektedir. Travma, mekanik ventilasyon ve cerrahi işlemler bu mikroorganizma için nozokomiyal enfeksiyonlarla ilgili önemli risk faktörleridir 2,3 . Fırsatçı patojen olarak çoklu ilaca dirençli A. baumannii infeksiyonlarının sayısı küresel olarak son yıllarda artmıştır. Nozokomiyal gram negatif patojenler içerisinde kontrol ve tedavisi en güç olanlardan biri haline gelmiştir 4,5 . A. baumannii salgınlarının pek çoğu hasta yatakları, klimalar ve mekanik ventilasyon ekipmanları gibi çevresel kaynaklıdır 6 . Acinetobacter spp.kuru cansız yüzeylerde 3 gün–5 ay arasında canlı kalabilir decrease in sensitivity to amikacin, ampicillin-sulbactam, cefepime, ceftriaxone, colistin and tigecycline, while sensitivity to other antibiotics was observed. Multiple antibiotic resistance was examined in a total of 237 A. baumannii isolated. Multidrug resistant MDR resistance was 92 %, Extensively Drug Resistant XDR resistance was 84 % and Pan Drug Resistant PDR resistance was 3 %.Conclusion: It is observed that resistance against some antibiotics has increased in A. baumannii over the years, and resistance to some antibiotics has decreased. It seems that our XDR resistance rate is very high. Our PDR resistance rate is higher than that of America, but lower than many European countries. In the other hand our result is lower than the average of Turkey

Keywords:

Acinetobacter infections, bacterial sensitivity test, multiple antibacterial drug resistance,

PDF

___

1. Peleg Anton Y, Harald Seifert, David L. Paterson. Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev, 2008;21(3):538-82.
2. Bergogne-Berezin E, Towner KJ. Acinetobacter baumannii.as nosocomial pathogens: microbiological, clinical, and epidemilogical features. Clin Microbiol Rev, 1996;9(2):148-65.
3. Parvez FM, Jarvis WR. Nosocomial infections in the nursery. Semin Pediatr Infect Dis, 1999; 10:119–29.
4. Jain R, Danziger LH. Multidrug-resistant Acinetobacter infections: an emerging challenge to clinicians. Ann Pharmacother, 2004;38(9):1449-59.
5. Li J, Nation RL, Milne RW, Turnidge JD, Coulthard K. Evaluation of colistin as an agent against multiresistant gram-negative bacteria. Int J Antimicrob Agents, 2005;25(1):11-25.
6. Villegas, Maria Virginia, and Alan I. Hartstein. Acinetobacter Outbreaks, 1977–2000. Infection Cont & Hosp Epidemiol, 2003;24(4):284-95.
7. Beck-Sague CM, Jarvis WR, Brook JH, Culver D. H, Potts A, Gay E et al. Epidemic bacteremia due to Acinetobacter baumannii in five intensive care unit. Am J Epidemiol, 1990;132(4):723-33.
8. Lortholary O, Fagon JY, Hoi AB, Slama M A, Pierre J, Giral Pet al. Nosocomial acquisition of multiresistant Acinetobacter baumannii: Risk factors and prognosis. Clin Infect Dis, 1995;20(4):790-6.
9. Siegman-Igra Y, Bar-Yosef S, Gorea A, Avram J. Nosocomial Acinetobacter meningitis secondary to invasive procedues: report of 25 cases and review. Clin Infect Dis, 1993;17(5):843-9.
10. Clinical and Laboratory Standards Institute. M100-S3 Performance Standards for Antimicrobial Susceptibility Testing; 23rd Informational Supplement, 9th. CLSI, Wayne, PA (2013).
11. Tünay H, Demirdal T, Demirtürk N. Acinetobacter enfeksiyonlarında dirençle ilgili değişen tanımlamalar ve dirençte güncel durum. Türk Mikrobiyol Cem Derg, 2012;42(4):123-6.
12. Magiorakos AP, Srinivasan A, Carey RB, Carmeli, Y, Falagas ME, Giske CG et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect, 2012;18(3):268-81.
13. Gootz TD, Marra A. Acinetobacter baumannii: an emerging multidrug-resistant threat. Expert Rev Anti Infect Ther, 2008;6(3):309-25.
14. https://hsgm.saglik.gov.tr/tr/duyurular/997- ulusal-sağlık-hizmeti-ilişkili-enfeksiyonlarsürveyans-ağı-etken-dağılımı-ve-antibiyotikdirenç-raporu-2017.html (erişim tarihi 11.05.2019).
15. Babaei A.H, Pouladfar G, Pourabbas B, Jafarpour Z, Ektesabi S, Abbasi P. Seven-Year Trend of Antimicrobial Resistance of Acinetobacter and Pseudomonas spp. Causing Bloodstream Infections: A Retrospective Study from Shiraz, Southern Iran. Jundish J Microbiol, 2019;12(4): 1-8.
16. Gales AC, Seifert H, Gur D, Castanheira M, Jones RN, Sader HS. (2019, March). Antimicrobial Susceptibility of Acinetobacter calcoaceticus–Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997–2016). In Open forum infectious diseases (Vol. 6, No. Supplement_1, pp. S34-S46). US: Oxford University Press.
17. Şahin AR, Doğruer D, Nazik S, Aktemur A, Öksüz H, Aral M ve ark. Hastane Kökenli Patojenlerde Artan Antimikrobiyal Direnç Sorunu: Acinetobacter baumannii. Online Türk Sağlık Bil Derg, 2019; 4(2): 156-169.